Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Chugh, R, Griffith, K A, Davis, E J, Thomas, D G, Zavala, J D, Metko, G, Brockstein, B, Undevia, S D, Stadler, W M, Schuetze, S M
Published in Annals of oncology (01.08.2019)
Published in Annals of oncology (01.08.2019)
Get full text
Journal Article
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Chugh, R., Griffith, K.A., Davis, E.J., Thomas, D.G., Zavala, J.D., Metko, G., Brockstein, B., Undevia, S.D., Stadler, W.M., Schuetze, S.M.
Published in Annals of oncology (01.07.2015)
Published in Annals of oncology (01.07.2015)
Get full text
Journal Article
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Chugh, R., Griffith, K.A., Davis, E.J., Thomas, D.G., Zavala, J.D., Metko, G., Brockstein, B., Undevia, S.D., Stadler, W.M., Schuetze, S.M.
Published in Annals of oncology (01.08.2019)
Published in Annals of oncology (01.08.2019)
Get full text
Journal Article